Catalys Pacific

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease, particularly targeting secondary hyperparathyroidism (SHPT). SHPT is a condition characterized by the overactivity of the parathyroid glands, resulting from diseases outside of these glands, leading to excessive production of parathyroid hormone (PTH). The company's lead product, upacicalcet, is a novel calcimimetic designed to improve treatment outcomes for hemodialysis patients by mimicking calcium's effects on tissues through the activation of calcium-sensing receptors found in various human organs. Pathalys aims to address significant unmet medical needs in the management of SHPT, ultimately enhancing the quality of care for patients with end-stage chronic kidney disease.

Arialys Therapeutics is a pre-clinical stage biotechnology company that specializes in neuroscience, particularly in the development of precision medicines aimed at blocking pathogenic autoantibodies in the brain. The company investigates the role of the immune system in central nervous system (CNS) health and disease, focusing on the characterization and prevalence of pathogenic auto-antibody activity. Arialys Therapeutics aims to provide advanced therapies for various CNS disorders, including neuropsychiatric conditions linked to autoimmune diseases, thereby contributing to the healthcare industry's efforts to address complex neurological challenges.

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease, particularly targeting secondary hyperparathyroidism (SHPT). SHPT is a condition characterized by the overactivity of the parathyroid glands, resulting from diseases outside of these glands, leading to excessive production of parathyroid hormone (PTH). The company's lead product, upacicalcet, is a novel calcimimetic designed to improve treatment outcomes for hemodialysis patients by mimicking calcium's effects on tissues through the activation of calcium-sensing receptors found in various human organs. Pathalys aims to address significant unmet medical needs in the management of SHPT, ultimately enhancing the quality of care for patients with end-stage chronic kidney disease.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease, particularly targeting secondary hyperparathyroidism (SHPT). SHPT is a condition characterized by the overactivity of the parathyroid glands, resulting from diseases outside of these glands, leading to excessive production of parathyroid hormone (PTH). The company's lead product, upacicalcet, is a novel calcimimetic designed to improve treatment outcomes for hemodialysis patients by mimicking calcium's effects on tissues through the activation of calcium-sensing receptors found in various human organs. Pathalys aims to address significant unmet medical needs in the management of SHPT, ultimately enhancing the quality of care for patients with end-stage chronic kidney disease.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Exalys Therapeutics is engaged in the development of innovative anti-inflammatory therapeutics aimed at addressing a variety of diseases that currently have significant unmet medical needs. The company is focusing on creating first-in-class therapies, with an initial emphasis on preventing postoperative delirium, a common complication among older surgical patients that can lead to adverse health outcomes. By targeting inflammatory disorders, including pain and renal dysfunction, Exalys aims to provide effective treatment options for conditions that are often serious and life-threatening, yet lack adequate therapies.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.